V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10007011 | 10004856 | 1.77 | 72.3 | Palliative (P) | null | 2018-05-27 | CAPECITABINE + CISPLATIN + Trastuzumab | N | N | 10487958 | MELPHALAN |
| 10007012 | 10004860 | 1.51 | 75.8 | Palliative (P) | 2018-11-27 | 2018-11-27 | CISPLATIN + FLUOROURACIL | N | N | 10487962 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB |
| 10007013 | 10004860 | null | 88.6 | null | 2018-04-12 | 2018-07-06 | CHOP R + METHOTREXATE | null | N | 10487962 | EOX |
| 10007014 | 10004860 | 1.87 | 96 | Disease modification (D) | 2016-05-13 | 2016-05-13 | Capecitabine 35days + RT | 02 | N | 10487962 | METHOTREXATE HIGH DOSE |
| 10007015 | 10004861 | 1.7 | 93.1 | Palliative (P) | 2019-04-13 | 2019-04-14 | Cetuximab + FLUOROURACIL + OXALIPLATIN | 2 | N | 10488337 | CISPLATIN + ETOPOSIDE |
| 10007016 | 10004861 | 1.61 | 52.6 | Adjuvant (A) | 2018-05-19 | 2018-05-28 | Cisplatin +Fluorouracil (3 wk) | N | N | 10488337 | DA |
| 10007017 | 10004862 | 1.5 | 85.8 | Palliative (P) | 2013-12-04 | 2013-12-23 | IPM | N | N | 10488669 | FEC |
| 10007018 | 10007450 | 1.85 | 73 | Palliative (P) | 2018-05-01 | 2018-05-02 | Sorafenib | N | N | 10488737 | IMATINIB |
| 10007019 | 10007450 | 1.69 | 97.7 | Palliative (P) | 2018-09-15 | 2018-10-09 | NIVOLUMAB | N | N | 10488737 | CYTARABINE + IDARUBICIN |
| 10007020 | 10004866 | 1.52 | 55 | Palliative (P) | 2017-09-14 | 2017-10-05 | Capecitabine + Cisplatin + RT | N | Y | 10488841 | GEFITINIB |
| 10007021 | 10004866 | 1.75 | 56.4 | null | 2016-03-06 | 2016-03-09 | Bortezomib + CYCLOPHOSPHAMIDE | 01 | N | 10488841 | ENRICH TRIAL |
| 10007022 | 10004867 | 1.83 | 67.4 | Palliative (P) | 2015-09-03 | 2015-10-04 | Fluorouracil+Mitomycin+RT (Bladder) | null | N | 10489007 | CISPLATIN + RT |
| 10007023 | 10004868 | 1.78 | 96.2 | Palliative (P) | 2017-10-15 | 2018-01-14 | ECX | N | N | 10489029 | EOX |
| 10007024 | 10004869 | 1.76 | 0 | Palliative (P) | null | 2016-11-07 | CETUXIMAB + IRINOTECAN + MDG | N | N | 10489038 | CAPECITABINE + GEMCITABINE |
| 10007025 | 10004870 | 1.57 | 64 | Palliative (P) | 2018-03-15 | 2018-03-29 | Bortezomib +/- Dexamethasone | N | N | 10489086 | PERTUZUMAB |
| 10007026 | 10007453 | 1.67 | 80.6 | Curative (C) | 2018-05-01 | 2018-09-08 | Cisplatin + Pemetrexed | N | N | 10489110 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN |
| 10007027 | 10004872 | 1.71 | 77.4 | Palliative (P) | 2015-09-19 | 2017-10-05 | Bortezomib +/- Dexamethasone | N | N | 10489172 | EOX |
| 10007028 | 10004872 | 1.76 | null | Adjuvant (A) | 2017-04-13 | 2017-04-16 | Methotrexate intrathecal | N | N | 10489172 | METHOTREXATE INTRATHECAL |
| 10007029 | 10004873 | 1.78 | 73 | null | 2017-06-24 | 2017-06-24 | CHLORAMBUCIL + RITUXIMAB | 02 | N | 10489184 | IXAZOMIB + LENALIDOMIDE |
| 10007030 | 10004874 | 1.74 | 85.5 | Palliative (P) | 2016-01-02 | 2016-01-08 | Cyclophosphamide High Dose | N | N | 10489253 | CHLORAMBUCIL |
| 10007031 | 10004875 | 1.86 | 0 | Adjuvant (A) | 2018-07-25 | 2018-08-22 | Cabazitaxel | 2 | N | 10489253 | MYELOMA XI TRIAL |
| 10007032 | 10004876 | 1.7 | 80.7 | Adjuvant (A) | 2016-09-22 | 2016-11-10 | Enzalutamide | 2 | N | 10489385 | CHOP |
| 10007033 | 10004876 | 1.8 | 74.5 | Palliative (P) | 2017-12-03 | 2017-12-17 | Mini BEAM | N | N | 10489385 | HCX |
| 10007034 | 10004876 | 1.73 | 60 | Palliative (P) | 2016-10-06 | 2017-01-06 | ATG + Busulfan + Fludarabine | N | N | 10489385 | CRIZOTINIB |
| 10007035 | 10004877 | 1.73 | 80 | Neo-adjuvant (N) | 2016-01-05 | 2017-03-09 | HCX (Cape + Cisp + Tras) - Load | N | N | 10489481 | PANITUMUMAB |
| 10007036 | 10004878 | 1.83 | null | Palliative (P) | 2017-09-11 | 2018-05-16 | CABOZANTINIB | 2 | N | 10489503 | CARBOPLATIN + DOCETAXEL |
| 10007037 | 10004880 | 1.73 | 63.2 | Palliative (P) | 2015-10-14 | 2015-10-25 | DA-EPOCH | N | N | 10489505 | ETOPOSIDE |
| 10007038 | 10007458 | 1.68 | 85.1 | Palliative (P) | 2017-01-31 | 2017-02-03 | Cisplatin + Gemcitabine (D 1 & 8) | N | N | 10489526 | THALIDOMIDE |
| 10007039 | 10004881 | 1.78 | 62.8 | Palliative (P) | 2017-06-28 | 2017-07-12 | Cetuximab + FOLFIRI cycle 2 onwards | Y | N | 10489526 | MELPHALAN |
| 10007040 | 10004882 | 1.99 | 69.5 | Palliative (P) | 2017-04-29 | 2017-05-18 | Enzalutamide | N | N | 10489682 | MELPHALAN |
| 10007041 | 10007460 | 1.78 | 64.2 | Not known (9) | 2018-06-14 | 2018-06-14 | Gemcitabine + Paclitaxel | 02 | Y | 10489705 | CHLORAMBUCIL + OBINUTUZUMAB |
| 10007042 | 10007460 | 1.78 | 70.5 | Palliative (P) | 2017-07-03 | 2017-07-03 | RCEOP | N | N | 10489705 | POMALIDOMIDE |
| 10007043 | 10004883 | 1.84 | 0 | Palliative (P) | 2018-02-21 | 2018-02-21 | Melphalan IV High dose | N | N | 10489824 | CETUXIMAB |
| 10007044 | 10007461 | 1.62 | 61.6 | Not known (9) | 2017-08-01 | 2017-08-02 | Lomustine | N | N | 10489871 | VEDEX |
| 10007045 | 10007462 | 1.54 | 54.4 | Adjuvant (A) | 2016-08-23 | 2016-08-26 | Hydroxycarbamide | N | N | 10489897 | DOCETAXEL + NINTEDANIB |
| 10007046 | 10004885 | 1.83 | 105 | Palliative (P) | 2018-04-07 | 2018-08-25 | Ipilimumab | 02 | N | 10489972 | EOX |
| 10007047 | 10004885 | 1.67 | 67.4 | Disease modification (D) | 2015-11-28 | 2015-12-03 | MYELOMA XI TRIAL | 02 | N | 10489972 | CETUXIMAB + IRINOTECAN + MDG |
| 10007048 | 10004886 | 1.75 | 0 | Curative (C) | 2015-03-24 | 2015-09-28 | ECX | 02 | N | 10490224 | LEAM |
| 10007049 | 10004887 | 1.79 | 0 | Adjuvant (A) | 2016-07-21 | 2016-07-27 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN | 02 | N | 10490318 | QUASAR 2 TRIAL |
| 10007050 | 10004889 | 1.75 | 69.3 | Curative (C) | 2015-04-14 | 2015-04-16 | Cisplatin 100 + RT(H&N) 1 day | null | N | 10490408 | CISPLATIN + GEMCITABINE |
| 10007051 | 10004889 | null | 135.5 | Palliative (P) | 2017-09-15 | 2017-09-18 | Cabazitaxel | 02 | N | 10490408 | SPIRE TRIAL |
| 10007052 | 10004889 | 1.76 | null | Palliative (P) | 2018-06-20 | 2018-07-04 | Methotrexate intrathecal | N | Y | 10490408 | CVD |
| 10007053 | 10004891 | 1.65 | 56 | Disease modification (D) | 2017-05-08 | 2017-05-10 | VEDex | N | N | 10490771 | DOXORUBICIN |
| 10007054 | 10004891 | null | 56 | Curative (C) | 2018-01-11 | 2018-01-14 | NIVOLUMAB | N | Y | 10490771 | METHOTREXATE INTRATHECAL |
| 10007055 | 10004893 | 1.67 | 74.9 | Palliative (P) | 2016-01-05 | 2016-02-02 | EOX | 2 | y | 10490845 | BENDAMUSTINE + CYTARABINE + ETOPOSIDE + MELPHALAN |
| 10007056 | 10004895 | 1.7 | 71.7 | Palliative (P) | 2016-10-22 | 2016-10-22 | CAV | N | null | 10490897 | SORAFENIB |
| 10007057 | 10004896 | 1.76 | 96.05 | Neo-adjuvant (N) | 2015-12-09 | 2016-04-08 | Enzalutamide | 02 | null | 10490921 | METHOTREXATE |
| 10007058 | 10004898 | 1.8 | null | Unknown (U) | 2015-11-03 | 2016-02-02 | Bortezomib + Panobinostat | N | N | 10490932 | CISPLATIN + GEMCITABINE |
| 10007059 | 10004899 | null | 70 | Palliative (P) | 2016-05-02 | 2016-05-12 | Bortezomib + CYCLOPHOSPHAMIDE | N | N | 10491022 | CETUXIMAB + IRINOTECAN + MDG |
| 10007060 | 10004900 | 1.75 | 74.2 | Adjuvant (A) | 2019-05-25 | 2019-06-05 | BEAM | N | N | 10491053 | CHLVPP |